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Abstract
Antigen presenting cells (APCs) play an important role in arthritis and APC specific gene therapeutic targeting will enable
intracellular modulation of cell activity. Viral mediated overexpression is a potent approach to achieve adequate transgene
expression levels and lentivirus (LV) is useful for sustained expression in target cells. Therefore, we studied the feasibility of
lentiviral mediated targeting of APCs in experimental arthritis. Third generation VSV-G pseudotyped self-inactivating (SIN)-
LV were injected intravenously and spleen cells were analyzed with flow cytometry for green fluorescent protein (GFP)
transgene expression and cell surface markers. Collagen-induced arthritis (CIA) was induced by immunization with bovine
collagen type II in complete Freund’s adjuvant. Effect on inflammation was monitored macroscopically and T-cell subsets in
spleen were analyzed by flow cytometry. Synovium from arthritic knee joints were analyzed for proinflammatory cytokine
expression. Lentiviruses injected via the tail vein preferentially infected the spleen and transduction peaks at day 10. A dose
escalating study showed that 8% of all spleen cells were targeted and further analysis showed that predominantly Ly6C+
and F4/80+ cells in spleen were targeted by the LV. To study the feasibility of blocking TAK1-dependent pathways by this
approach, a catalytically inactive mutant of TAK1 (TAK1-K63W) was overexpressed during CIA. LV-TAK1-K63W significantly
reduced incidence and arthritis severity macroscopically. Further histological analysis showed a significant decrease in bone
erosion in LV-TAK1-K63W treated animals. Moreover, systemic Th17 levels were decreased by LV-TAK1-K63W treatment in
addition to diminished IL-6 and KC production in inflamed synovium. In conclusion, systemically delivered LV efficiently
targets monocytes and macrophages in spleen that are involved in autoimmune arthritis. Moreover, this study confirms
efficacy of TAK1 targeting in arthritis. This approach may provide a valuable tool in targeting splenic APCs, to unravel their
role in autoimmune arthritis and to identify and validate APC specific therapeutic targets.
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Introduction
Inflammatory diseases, such as rheumatoid arthritis, are
characterized by infiltration of leukocytes into the inflamed tissue
consisting of various immune cells from both the innate and
adaptive immune system. Macrophages in arthritis have been
extensively studied and play an important role in maintaining
inflammation and joint destruction [1;2]. Moreover, a general
approach of macrophage specific targeting with lipoplexes
ameliorates experimental arthritis [3;4].
Specifically modulating macrophage activity during inflamma-
tory conditions is a suitable approach to limit systemic side effects
of treatment. In addition, gene therapy can be a powerful
technique to achieve intracellular modulation of protein expres-
sion or signaling. Effective gene therapeutic treatment of collagen-
induced arthritis has been achieved by ectopic overexpression of
suppressor of cytokine signaling 3 (SOCS3) in splenic antigen
presenting cells (APCs) [5]. In addition, knock down of TNF
receptor I by overexpression of a short hairpin was also effective in
ameliorating experimental arthritis [6]. Both studies used adeno-
viral vectors, ensuring a high, but transient transgene overexpres-
sion. Over recent years, HIV based lentiviral vectors have been
optimized regarding safety and production and proved to be a
valuable tool in order to get long term transgene expression.
Multiple studies have evaluated the feasibility of intravenous
injection of lentivirus. These studies shown that the spleen is one of
the organs predominantly targeted by lentivirus injected intrave-
nously [7]. Further analysis on localization on GFP expression in
the spleen showed large fluorescent clusters overlapping the
marginal zone [8]. Cell surface markers revealed that mostly
MHC-II positive cells were targeted by lentivirus [8;9], indicating
preferential targeting of APCs by lentivirus.
Specific targeting of APCs by lentivirus makes it possible to
study the role of these APCs in inflammatory conditions. In
addition, specific interference with gene expression can possibly
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identify new therapeutic targets in APCs. To validate macrophage
targeting a known potent therapeutic target was used, TGF-beta
activated kinase 1 (TAK1). This MAP kinase is a key signaling
protein as it is used by many pro-inflammatory signals. Toll-Like
receptor and cytokine receptor activates intracellular signaling
which converges to TAK1 and subsequently activate AP-1 and
NF-kB. Therefore, TAK1 poses a compelling target to block pro-
inflammatory signaling. Moreover, TAK1 has been shown to be
important in autoimmune arthritis [3] and is a suitable target to
validate macrophage specific targeting by lentiviral vectors.
In this study, we validated intravenous lentivirus injections into
DBA1/J mice by determining expression kinetics, a dose escalating
study, and analysis of targeted cells. This has shown that
predominantly splenic F4/80+ and Ly-6C+ cells are targeted by
this approach. To evaluate the gene therapeutic potential of LV-
mediated targeting of splenic APCs, a TAK1 kinase negative
mutant (TAK1-K63W) was over expressed during collagen-
induced arthritis. TAK1-K63W decreased knee joint inflamma-
tion macroscopically and systemic Th17 levels in the spleen were
reduced. In addition, bone erosion was diminished by TAK1-
K63W and pro-inflammatory cytokine expression in synovial
tissue was decreased. This study shows that intravenous delivery of
lentiviral vectors enables evaluation of therapeutic targets in




All in vivo studies complied with national legislation and were
approved by local authorities (Animal Ethics Committee, Rad-
boud University Nijmegen. Permit number: 2009-177) for the care
and use of animals with related codes of practice.
Mice
Male DBA/1 mice aged 10–12 weeks (Janvier, Elavage, France)
were housed in top-filter cages and fed a standard diet with freely
available food and water.
Induction and monitoring of collagen-induced arthritis
Bovine type II collagen was dissolved in 0.05 M acetic acid to a
concentration of 2 mg/ml and was emulsified in equal volumes of
Freund’s complete adjuvant (2 mg/ml of Mycobacterium tuber-
culosis strain H37Ra) (Difco, Detroit, MI) Mice were immunized
intradermally at the base of the tail with 100 ul of emulsion (50 ug
of bovine type II collagen). Subsequently, mice were given an
intra-peritoneal booster injection of 100 ug of type II collagen
dissolved in phosphate buffered saline (PBS) on day 21. Two
independent observers monitored clinical signs of arthritis in paws
and ankle joints, macroscopically. Cumulative scoring based on
redness, swelling, and, in later stages, ankylosis was as follows:
0 = no changes; 0.25= 1–2 toes red or swollen; 0.5 = 3–5 toes red
or swollen; 0.5 = swollen ankle; 0.5 = swollen footpad; 0.5 = severe
swelling and ankylosis, with a maximal score of 2 per paw.
Plasmids
For generation of recombinant lentiviral vectors we used of the
third-generation self-inactivating transfer vector pRLL-cPPT-
PGK-mcs-PRE-SIN (PGK-empty) containing the human phos-
phoglyceratekinase (PGK) promoter (kind gift from J. Seppen,
AMC Liver Center, Amsterdam, The Netherlands). For cloning
we used cloned Pfu DNA polymerase (Stratagene, La Jolla, CA)
and T4 DNA Ligase (New England Biolabs, Ipswich, MA). All
generated constructs were verified by sequencing. The cDNA
sequences of a kinase-inactive mutant of human TAK1 (K63W)
were PCR cloned from pEGFP-C1-TAK1-K63W into NheI/NsiI
sites of PGK-SIN using the following primers: RV 59-ATG-
CATTCATGAAGTGCCTTGTCAG-39, FW 59-GCTAGCGC-
CACCATGTCGACA GCCTCCGCCGCC-39 (non-tagged, Ko-
zak sequence for enhanced translation introduced).
Lentiviral vector production
Packaging of VSV-G pseudotyped recombinant lentiviruses was
performed by transient transfection of 293T cells. One day prior to
transfection, 293T cells were seeded in a T75 flask at 16105 cells/
cm2 in DMEM supplemented with 10% FCS, 1 mM pyruvate,
40 mg/ml gentamicin and 0.01 mM water-soluble cholesterol
(Sigma). Cells were co-transfected with 19 mg transfer vector,
14 mg gag/pol packaging plasmid (pMDL-g/p-RRE), 4.7 mg rev
expression plasmid (RSV-REV) and 6.7 mg VSV-G expression
plasmid (pHIT-G) by calcium phosphate precipitation. Transfec-
tions were performed in 6 ml DMEM without antibiotics and
cholesterol and cultured for 16 hours. Thereafter medium was
replaced with fully supplemented DMEM and supernatant
harvested after 24 and 48 hours. Cell debris was removed by
centrifugation at 1500 rpm for 5 minutes at 4uC, followed by
passage through a 0.45 mm pore polyvinylidene fluoride Durapore
filter (Millipore, Bedford, MA, USA). For concentration by
ultracentrifugation 28 ml supernatant was overlaid on 4 ml 20%
sucrose solution and centrifuged at 25.000 rpm for four hours in a
Surespin 630 rotor (Thermo Fisher Scientific, Waltham, MA).
Pelleted viruses were resuspended in sterile PBS and stored at
280uC. Viral titers were determined by assaying p24gag values
with a commercial enzyme-linked immunosorbent assay (ELISA)
kit (Abbott Diagnostics, Hoofddorp, the Netherlands) and
expressed as ng p24gag/ml.
In vivo imaging
In vivo bioluminescent imaging was performed on an IVIS
Lumina system (Caliper Life Sciences, Hopkinton, MA, USA),
10 minutes after intraperitoneal injection of 150 mg/kg D-
Luciferine (Caliper Life Sciences) dissolved in PBS. Mice were
anesthetized with isoflurane/oxygen, placed on their back into the
light tight chamber and imaged for 4 minutes with a sensitive
CCD camera. Images taken were quantified using the Living
Image 3.0 software (Caliper Life Sciences). Luciferase activity is
presented in photons emitted per second per square cm.
RNA isolation and quantitative PCR analysis
Spleen, synovium, and liver samples were disrupted using the
MagNaLyser (Roche). Total RNA was extracted from the tissue
homogenates and from cells using TRI reagent (Sigma) according
to manufacturer’s protocol. Isolated RNA was treated with DNAse
followed by reverse transcription of 1 mg RNA into cDNA using
Moloney murine leukemia virus reverse transcriptase 0.5 mg/ml
oligo(dT) primers, and 12.5 mM dNTPSs (Invitrogen). Quantita-
tive real-time PCR was performed using the StepOnePlus
sequence detection system (Applied biosystems, Foster City, CA)
PCR was performed in a total reaction volume of 12.5 ml
consisting of appropriate cDNA. Five mM of forward and reverse
primer and the sYBR green PCR master mix (Applied biosystems).
PCR protocol consisted of 2 min at 50uC and 10 min of 95uC,
followed by 40 cycles of 15 sec at 95uC and 1 min at 60uC.
Quantification of PCR signals was achieved by calculating the
difference between the cycle threshold value (Ct) of the gene of
interest with the Ct value of their reference gene glycerldehyde-3-
phophate dehydrogenase (GAPDH) for each sample (delta Ct)
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Histology
Spleens were isolated and fixed in phosphate buffered 4%
paraformaldehyde and embedded in paraffin wax. Whole knee
joints were dissected and fixed in phosphate buffered 4%
paraformaldehyde followed by decalcification with 5% formic
acid, and embedded in paraffin wax. Serial tissue sections (7 mm)
were stained with Safranin O (BDH chemicals, Poole, UK) and
counterstained with fast green (BHD Chemicals) or with
hematoxylin/eosin (Merck, Germany) and eosin (Merck, Ger-
many) (H&E). Serial sections were scored for histopathological
changes on a 0-3 scale, by 2 independent observers in a blinded
manner. Joint inflammation was determined by the presence of
synovial cell infiltrates and inflammatory cell exudates. Connective
tissue destruction was determined by cartilage and bone erosion.
FACS analysis
Spleens from mice were mashed, filtered and erythrocytes were
removed by osmotic shock and directly stained for GFP expression
and CD3 (1:200 eBioscience), CD19 (1:50 BD Pharmingen), F4/
80 (1:400, Biolegend), and Ly-6C (1:800, Biolegend) cell surface
markers. For T-cell subset analysis in arthritic mice CD3+ cells
were isolated from spleen using the Pan T cell Isolation Kit
(Miltenyi Biotec, Germany) according to manufacturer instruc-
tions. Purified CD3+ cells were stimulated in RPMI 1640
(Invitrogen) supplemented with 10% FCS penicillin/streptomycin
and pyruvate with 50 ng/ml PMA, 1 ul/ml/10‘6 cells Brefeldin A
(BD Pharmingen) and 1 ug/ml ionomycin. After 4 hours of
stimulation cells were stained with anti-mouse CD4-APC (1:200)
(BD Pharmingen) or IgG2a-APC control (BD Pharmingen) for
30 minutes at 4uC. Subsequently, cells were stained intracellular
with anti-IL17-FITC and anti-IFNc-PE or with their controls
respectively IgG1-PE and IgG1-FITC according to instructions by
manufacturer (BD Pharmingen). Stained cells were analyzed using
FACScalibur (Becton Dickinson) and analyzed with FlowJow
software.
Bone marrow derived dendritic cells
Femurs and tibias of DBA1/J mice were flushed and bone
marrow was harvested. After preparing a single cell suspension
cells were plated (250,000 c ells per cm2) with 833 ng p24GAG
equivalent and 20 ng/ml GM-SCF. Medium was changed on day
4 and day 8.
Statistics
Statistical differences were determined by one-way ANVA or
student’s T-test (two sided) and GraphPad 5.0 software. P values
below 0.05 were considered significant.
Results and Discussion
Expression kinetics is dependent on route of
administration
Although previous studies have shown efficient transduction of
spleen cells by intravenously delivered lentivirus, there are
considerable differences between Balb/c and C57Bl/6 mice
[10]. Therefore the kinetics of lentiviral mediated transgene
Figure 1. Transgene expression kinetics. Every animal received 10 mg of p24GAG equivalent of lentivirus encoding firefly luciferase
intravenously. Luciferase activity was determined after injection of luciferine using biophotonic imaging with the IVIS Lumina. Region of interest was
placed over abdomen of mice. Kinetics of transgene expression (A) and organ distribution of transduction (B) after lentivirus injection via the retro
orbital sinus, n = 6. B). Comparison between retro orbital sinus and tail vein injection (n = 2 in both groups) for abdominal expression (C) and
localization of transgene expression in tail vein injected animals (D).
doi:10.1371/journal.pone.0055356.g001
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expression needs to be determined in DBA1/J mice, an
autoimmune prone strain used for the CIA model. We injected
10 mg p24GAG equivalent (approximately 5610‘8 viral particles)
of lentivirus encoding luciferase intravenously via the retro orbital
sinus and luciferase activity was determined by in vivo imaging.
Figure 1A shows that maximal luciferase activity was reached at
day 7 after virus injection. Organ distribution of the luciferase
activity is shown in Figure 1B and strikingly a substantial level of
luciferase activity was found around the throat of the animals.
These are possibly the submandibular lymph nodes draining the
eye, but the precise localization was not identified. To avoid
targeting this particular site and achieve more efficient delivery of
LV to the spleen the retro orbital sinus injection site was compared
with tail vein injections. Figure 1C shows that the expression
kinetics of lentivirus injected via tail vein in spleen and liver are
different from injection via retro orbital sinus. Maximal luciferase
activity peaks at day 10 and expression levels of luciferase were
elevated compared to retro orbital sinus injections. Tail vein
injection also showed more luciferase activity in the liver and
spleen area (Figure 1B and 1D). Unexpectedly, luciferase activity
was also detected around the knee joint. This is most likely to
originate from the bone marrow, as these cells are also transduced
by lentivirus injected intravenously [7;10;11]. Additionally, these
results were also observed with retro orbita plexus injections (data
not shown). It appears that injection of lentivirus via the tail vein
favors transgene expression levels and location and all subsequent
experiments were performed with tail vein injections. Injection
directly into a vein is potentially preferable over retro orbital sinus
as the distribution of the lentivirus throughout the body is better
than into a sinus, which has a slow blood flow.
Dose escalating study of lentivirus
After establishing the delivery route and transgene expression
kinetics the optimal dose was determined by injecting increasing
doses of lentivirus encoding GFP. Figure 2A shows that increasing
doses of lentivirus also resulted in increasing percentage of GFP
positive cells in spleen with 7.4% of total spleen cells were GFP
positive when injected with 40 mg of p24GAG equivalent of
lentivirus. Analysis of the GFP mRNA expression showed an
increase in GFP mRNA with increasing dose of lentivirus, except
at 10 mg lentivirus due to large variation. In addition, GFP mRNA
expression showed a 12 fold increase in spleen compared to liver
samples when administered 40 mg LV per animal (Figure 2B).
Together with the luciferase activity measurements shown in
Figure 1D we concluded that lentivirus efficiently transduces cells
in the spleen. Although maximal expression of GFP was not
reached we used 40 mg of p24GAG LV per animal in subsequent
as a safe dose showing no side effects. GFP is known to elicit a
specific immune response [12], but no increase in splenic cell
number was observed in the dose escalating study (data not
shown).
Macrophages and monocytes are preferentially targeted
by lentivirus
Immunohistochemistry was done to determine the location of
GFP expression in the spleen. Figure 3A shows that with
increasing dose of lentivirus also more GFP protein is detected.
GFP expression was detected around the white pulpa near the
marginal zone, in line with other reports [8;13]. In a separate
experiment it was determined which cells are targeted by lentivirus
in the spleen, leukocytes were isolated from spleen and GFP
expression was determined in combination with cell surface
markers (Figure 3B). This confirmed that lentivirus only margin-
ally targets T- and B-cells, since the IHC showed that there was no
GFP expression in the white pulpa of the spleen. In contrast, it
appears that lentivirus preferentially targets F4/80+ and Ly-6C+
cells as 30–40% of cell populations were GFP positive. The GFP
expression in F4/80+ cells remains stable for up to ten days after
virus injection (data not shown). This preferential targeting of the
APC population has also been described by others [8;9]. The
monocyte population shows a sharp drop off in GFP expression
between day 4 and 7 after virus injection. This probably reflects
migration or differentiation of Ly-6C+ monocytes, whereas the
F4/80 expressing macrophages present in the red pulpa reside in
the spleen [14]. The antigen presenting cell (APC) population in
the spleen consists of many different subtypes of dendritic cells and
macrophages. Here, we show a preferential targeting of the
macrophage and monocyte population, but identification of the
exact APC subpopulation remains to be determined.
Lentivirus targets cells that play an important role during
arthritis
Next, we evaluated if the targeted cells also play a functional
role in inflammatory diseases. Therefore mice immunized with
bovine collagen type II were injected with lentivirus encoding a
kinase negative mutant of TAK1 (TAK1-K63W) to decrease
inflammatory signaling by Toll-Like Receptors and cytokines. This
target was identified as an important signaling molecule in
Figure 2. Dose finding of intravenous lentivirus injection.
Increasing doses of lentivirus encoding GFP were injected via the tail
vein and GFP expression was analyzed 10 days after injection. A) Total
spleen cells were analyzed by flow cytometry for GFP expression.
Statistics: one-way ANOVA with Bonferonni post test compared to PBS
injected animals, n = 4 per group. ** p,0.01, *** p,0.001. B) GFP mRNA
expression in liver and spleen samples. Relative expression = 22DCt.
Data represented as mean6SEM.
doi:10.1371/journal.pone.0055356.g002
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Figure 3. Localization splenic GFP expression and identification of transduced cell types by cell surface marker analysis. A)
Increasing doses of lentivirus encoding GFP were injected via the tail vein and GFP expression was analyzed by immunohistochemistry ten days after
virus injection. Representative histological images of experiment (magnification 2006), dotted line outlines white pulpa. W = white pulpa, R = red
pulpa. Arrow heads indicate GFP positive cells. B) Flow cytometric analysis of GFP expressing cells 4 and 7 days after virus injection. Data represented
as average (6SEM) GFP positive cells in gate indicated on x-axis (n = 4). C) Representative plots of cell marker and GFP FACS analysis.
doi:10.1371/journal.pone.0055356.g003
Lentiviral Targeting of APCs Ameliorates Arthritis
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e55356
experimental arthritis and provides a suitable target to study the
efficacy of intravenous injection of lentivirus [3]. Figure 4A shows
that disease incidence is decreased in animals injected with
lentivirus overexpressing the negative TAK1 mutant. In addition,
macroscopic swelling of the knee joints was significantly decreased
at time of sacrifice (Figure 4B). Further histological analysis
(Figure 4C–E) showed only a trend towards decreased inflamma-
tion and cartilage erosion. Bone erosion, however, was signifi-
cantly decreased in mice treated with TAK1-K63W. This is in line
with the altered Th17 population, which plays an important role
Figure 4. Effect of splenic TAK1 targeting on arthritis incidence and knee joint swelling. A) Arthritis incidence was monitored over time
macroscopically. B) Swelling of knee joints macroscopically at time of sacrifice (day 30 of CIA). Data represented as mean6SEM. Statistics macroscopic
scoring: Student’s t-test, n = 7 per group. ** p,0.01. C–E) Knee joints were isolated and evaluated for pathohistological features. C) Inflammation
scores determined on HE stained sections. D) Cartilage erosion scores determined on safranin-O stained sections. E) Bone erosion scores determined
on safranin-O stained sections. F-G) Representative histological images for bone erosion of knee joints. Original magnification 1006. Bone erosion
indicated with arrow head. P = patella, F = femur. Statistics histology: Student’s t-test, n = 8 for GFP, n = 6 for TAK1-K63W. * p,0.05.
doi:10.1371/journal.pone.0055356.g004
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in osteoclast activity and bone erosion [15]. In addition, Ly-6C
positive cells are precursors of osteoclasts [16] and inhibition of
pro-inflammatory signaling on these cells possibly also inhibits
osteoclast formation. A strong trend is found towards decreased
levels of cell influx into the joint and Swirski and colleagues have
described a pool of cells in the spleen that migrate towards the site
of inflammation [17]. These cells were CD11b and Ly-6C positive
and we have found Ly-6C+ cells expressing GFP after lentivirus
administration (Figure 3B). Additionally, Ly6C-high expressing
monocytes are attracted to the site of inflammation from the bone
marrow in a kidney injury model [18]. Taken together, lentivirus
injected intravenously could possibly target this pool of migrating
monocytes in the spleen.
Local inflammation decreased upon lentiviral targeting
of macrophages and monocytes
From the inflamed joints synovium was extracted and mRNA
analysis showed that proinflammatory cytokine mRNA expression
was decreased when mice were treated with lentivirus encoding
the TAK1 mutant (Figure 5). Although not significant, IL-1b
production shows a trend towards diminished production in the
inflamed synovium and might underlie the trend in decreased
cartilage erosion. The decrease in IL-6 production also supports
the diminished levels of Th17, as IL-6 is a crucial factor for Th17
development [19]. Moreover, RANK and RANK ligand, impor-
tant for osteoclast formation and function are decreased in
synovium of inflamed knee joints (Figure 6B) [20]. Together with
altered systemic Th17 levels, this possibly causes the decrease in
bone erosion. Additionally, production of the chemokine KC is
significantly reduced and possibly explains the clear trend in
reduced inflammation observed on histology. This shows that
targeting the macrophages and monocytes in the spleen and liver
can have distal effects on the inflamed tissue and shows the
importance of this cell population in experimental arthritis.
Lentivirus targets cells controlling the adaptive immunity
To study if the targeted cells are involved in controlling the
adaptive immunity, T-cell subsets were determined in the spleen.
At a systemic level, the TAK1 mutant had only marginally effects
on Th1 development in the spleen. However, Th17 cell
population was significantly decreased in the spleen by overex-
pression of the TAK1 mutant (Figure 6A). This suggests that
lentivirus delivered intravenously also targets cells that are
involved in controlling the adaptive immunity. This is in line
with previous studies that showed transduction of MHC-II+ cells
in spleen [9] and targeting of dendritic cell precursors and
influence T-cell proliferation [21]. In addition, systemic lentivirus
delivery has been used to induce tolerance in collagen-induced
arthritis and showed clear potential in affecting T-cell function,
with decreased proliferation [11].
Bone marrow derived DCs express reduced levels of IL-12
and IL-23
To evaluate how TAK1-K63W overexpression interferes with
activation of the adaptive immunity we generated bone marrow
derived DCs transduced with LV-GFP or LV-TAK1-K63W.
These DCs were analyzed for IL-12p35, IL-12p40, and IL-23p19
mRNA expression and showed diminished levels of IL-12p35 and
IL-23p19 and an increase in the IL-12p40 subunit (Figure 7).
These decreased levels could cause the decrease in Th1 and Th17
development during the CIA. Additionally, the increase in IL-
12p40 could enhance the inhibition on Th1 and Th17 develop-
ment, since the IL-12p40 subunit can antagonize the function of
IL-12 [22] and IL-23 [23]. These data show an important role for
TAK1 in DCs in controlling the adaptive immunity.
TAK1 as therapeutic target in arthritis has been established by
Courties and colleagues [3], in which TAK1 expression was
knocked down using RNA interference and ameliorated collagen-
induced arthritis. That study also showed altered T-cell subsets
upon TAK1 targeting in APCs, but also showed a more efficacious
therapy on arthritis severity. In the present study we overexpressed
a negative mutant of TAK1 which is a competitive mutant and
complete blockade of TAK1 cannot be achieved. In addition,
lentivirus tropism is possibly more selective than lipoplexes.
Nevertheless, we find matching results with TAK1 targeting in
collagen-induced arthritis.
Interestingly, a novel role for TAK1 has been described recently
[24;25]. Both studies have investigated the role of TAK1 in the
production of pro-inflammatory cytokines and, remarkably,
TAK1 negatively regulates cytokine production in myeloid cells.
In these studies used lipopolysaccharide was used as stimulus,
Figure 5. Proinflammatory cytokine expression in synovium of
arthritic animals. Synovium was isolated from arthritic animals and
disrupted. Total mRNA was isolated and analyzed for A) cytokines (IL-1b,
IL-6, KC) and B) RANK, and RANKL mRNA expression. Data represented
as mean6SEM. Relative expression = 22DCt. Statistics: Student’s t-test,
n = 6. * p,0.05.
doi:10.1371/journal.pone.0055356.g005
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which is a very potent activator of neutrophils and macrophages.
In addition, cytokine production was only determined over
24 hours. In contrast, collagen-induced arthritis involves a more
complex process than a single stimulation and the clinical features
of collagen-induced arthritis were studied for 12 days on our study.
In summary, this study shows an effective method to target a
monocyte and macrophage population in spleen that is involved in
inflammation and immunity. Blocking almost all pro-inflammato-
ry signals, by overexpression of a TAK1 mutant, disrupts
progression of experimental arthritis and impairs T-helper cell
Figure 7. IL-12 and IL-23 mRNA expression decreased in bone marrow derived DCs. Bone marrow cells were harvested and transduced
with either LV-GFP or LV-TAK1-K63W and subsequently differentiated into dendritic cells. After ten day differentiation period, mRNA was collected
and analyzed for basal expression of IL-12p35, IL-12p40, and IL-23p19 using RT-PCR as described in Material and Methods. Data represented as
mean6SEM, Relative expression = 22DCt, n = 2.
doi:10.1371/journal.pone.0055356.g007
Figure 6. T-cell subsets in spleen during arthritis after TAK1 targeting in splenic APCs. A) Spleen cells were isolated and stimulated with
PMA, ionomycin, and Brefeldin A for 4 hours and subsequently stained for CD4, IFNc, and IL-17. Percent positive cells from CD4 gate is shown. B)
Representative FACS analysis plots. IL-17 and IFNc positive cells in CD4+ gate shown. Data represented as mean6SEM. Statistics: Student’s t-test, two
tailed, n = 7. * p,0.05.
doi:10.1371/journal.pone.0055356.g006
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development. Injection of lentivirus intravenously provides a
straightforward tool to study potential therapeutic targets in
monocytes and macrophages during inflammatory conditions.
Additionally, this study confirms the efficacy of TAK1 targeting in
arthritis and emphasizes the role of this crucial MAP kinase in
monocytes and macrophages during autoimmune arthritis.
Acknowledgments
We would like to thank Alinda Berends for her excellent technical support.
Author Contributions
Final approval of manuscript: WvdB.. Conceived and designed the
experiments: BvdB FvdL. Performed the experiments: BvdB EV CW
OA MB. Analyzed the data: BvdB EV. Contributed reagents/materials/
analysis tools: MK. Wrote the paper: BvdB FvdL.
References
1. Hofkens W, Grevers LC, Walgreen B, de Vries TJ, Leenen PJ, et al. (2011)
Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and
bone erosion in murine antigen-induced arthritis. J Control Release 152: 363–
369.
2. van Lent PL, Krijger GC, Hofkens W, Nievaart VA, Sloetjes AW, et al. (2009)
Selectively induced death of macrophages in the synovial lining of murine knee
joints using 10B-liposomes and boron neutron capture synovectomy. Int J Radiat
Biol 85: 860–871.
3. Courties G, Seiffart V, Presumey J, Escriou V, Scherman D, et al. (2010) In vivo
RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells
through targeting of myeloid cells. Blood 116: 3505–3516.
4. Anderson R, Franch A, Castell M, Perez-Cano FJ, Brauer R, et al. (2010)
Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of
water-soluble dexamethasone phosphate in experimental adjuvant arthritis.
Arthritis Res Ther 12: R147.
5. Veenbergen S, Bennink MB, de Hooge AS, Arntz OJ, Smeets RL, et al. (2008)
Splenic suppressor of cytokine signaling 3 transgene expression affects T cell
responses and prevents development of collagen-induced arthritis. Arthritis
Rheum 58: 3742–3752.
6. Arntz OJ, Geurts J, Veenbergen S, Bennink MB, van den Brand BT, et al.(2010)
A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the
reticuloendothelial system in mediating experimental arthritis. Arthritis Res
Ther 12: R61.
7. Follenzi A, Sabatino G, Lombardo A, Boccaccio C, Naldini L (2002) Efficient
gene delivery and targeted expression to hepatocytes in vivo by improved
lentiviral vectors. Hum Gene Ther 13: 243–260.
8. Kimura T, Koya RC, Anselmi L, Sternini C, Wang HJ, et al. (2007) Lentiviral
vectors with CMV or MHCII promoters administered in vivo: immune
reactivity versus persistence of expression. Mol Ther 15: 1390–1399.
9. VandenDriessche T, Thorrez L, Naldini L, Follenzi A, Moons L, et al. (2002)
Lentiviral vectors containing the human immunodeficiency virus type-1 central
polypurine tract can efficiently transduce nondividing hepatocytes and antigen-
presenting cells in vivo. Blood 100: 813–822.
10. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, et al. (2004)
Targeting lentiviral vector expression to hepatocytes limits transgene-specific
immune response and establishes long-term expression of human antihemophilic
factor IX in mice. Blood 103: 3700–3709.
11. Gjertsson I, Laurie KL, Devitt J, Howe SJ, Thrasher AJ, et al. (2009) Tolerance
induction using lentiviral gene delivery delays onset and severity of collagen II
arthritis. Mol Ther 17: 632–640.
12. Annoni A, Battaglia M, Follenzi A, Lombardo A, Sergi-Sergi L, et al. (2007) The
immune response to lentiviral-delivered transgene is modulated in vivo by
transgene-expressing antigen-presenting cells but not by CD4+CD25+ regula-
tory T cells. Blood 110: 1788–1796.
13. Brown BD, Cantore A, Annoni A, Sergi LS, Lombardo A, et al. (2007) A
microRNA-regulated lentiviral vector mediates stable correction of hemophilia
B mice. Blood 110: 4144–4152.
14. Lloyd CM, Phillips AR, Cooper GJ, Dunbar PR (2008) Three-colour
fluorescence immunohistochemistry reveals the diversity of cells staining for
macrophage markers in murine spleen and liver. J Immunol Methods 334: 70–
81.
15. Koenders MI, Devesa I, Marijnissen RJ, bdollahi-Roodsaz S, Boots AM, et al.
(2008) Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in
interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 58: 3461–
3470.
16. de Vries TJ, Schoenmaker T, Hooibrink B, Leenen PJ, Everts V (2009) Myeloid
blasts are the mouse bone marrow cells prone to differentiate into osteoclasts.
J Leukoc Biol 85: 919–927.
17. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, et
al. (2009) Identification of splenic reservoir monocytes and their deployment to
inflammatory sites. Science 325: 612–616.
18. Lin SL, Castano AP, Nowlin BT, Lupher ML Jr, Duffield JS (2009) Bone
marrow Ly6Chigh monocytes are selectively recruited to injured kidney and
differentiate into functionally distinct populations. J Immunol 183: 6733–6743.
19. Kimura A, Kishimoto T (2010) IL-6: regulator of Treg/Th17 balance.
Eur J Immunol 40: 1830–1835.
20. Dimitrova P, Ivanovska N, Belenska L, Milanova V, Schwaeble W, et al. (2012)
Abrogated RANKL expression in properdin-deficient mice is associated with
better outcome from collagen-antibody induced arthritis. Arthritis Res Ther 14:
R173.
21. Arce F, Rowe HM, Chain B, Lopes L, Collins MK (2009) Lentiviral vectors
transduce proliferating dendritic cell precursors leading to persistent antigen
presentation and immunization. Mol Ther 17: 1643–1650.
22. Gillessen S, Carvajal D, Ling P, Podlaski FJ, Stremlo DL, et al. (1995) Mouse
interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol
25: 200–206.
23. Shimozato O, Ugai S, Chiyo M, Takenobu H, Nagakawa H, et al. (2006) The
secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions
and abrogates IL-23-mediated antitumour effects. Immunology 117: 22–28.
24. Eftychi C, Karagianni N, Alexiou M, Apostolaki M, Kollias G (2012) Myeloid
TAK1 acts as a negative regulator of the LPS response and mediates resistance
to endotoxemia. PLoS One 7: e31550.
25. Ajibade AA, Wang Q, Cui J, Zou J, Xia X, et al. (2012) TAK1 negatively
regulates NF-kappaB and p38 MAP kinase activation in Gr-1+CD11b+
neutrophils. Immunity 36: 43–54.
Lentiviral Targeting of APCs Ameliorates Arthritis
PLOS ONE | www.plosone.org 9 February 2013 | Volume 8 | Issue 2 | e55356
